Table 4.

The effect of HDS-2 and HDS-3 on enterocytic permeability (P_app and ER) of paclitaxel in the Caco-2 permeability experiment. ^∗P < 0.05 versus PTX group.

Group	Agents		Papp (×10−6 cm/s)		Efflux ratio ER
	Targeted agent	Combinative agents	AP–BL	BL–AP
PTX	Paclitaxel 1 μg/mL	—	0.25 ± 0.43	75.26 ± 7.43	299.26 ± 34.25
PTX + VRP	Paclitaxel 1 μg/mL	Verapamil 100 μM	30.85 ± 4.08∗	49.01 ± 16.15∗	1.59 ± 0.18∗
PTX + HDS-2	Paclitaxel 1 μg/mL	HDS-2 80 μg/mL	14.45 ± 1.83∗	33.72 ± 4.52∗	2.33 ± 0.55∗
PTX + HDS-2	Paclitaxel 1 μg/mL	HDS-2 20 μg/mL	3.31 ± 0.30∗	49.24 ± 5.12∗	14.89 ± 0.53∗
PTX + HDS-3	Paclitaxel 1 μg/mL	HDS-3 80 μg/mL	9.21 ± 1.88∗	34.06 ± 7.76∗	3.70 ± 0.43∗
PTX + HDS-3	Paclitaxel 1 μg/mL	HDS-3 20 μg/mL	0.23 ± 0.20	35.02 ± 9.53∗	150.62 ± 17.98